凯莱英医药集团（天津）股份有限公司 舆情管理制度 （2024 年 9 月） 凯莱英医药集团（天津）股份有限公司 舆情管理制度 第一章 总则 第一条 为提高凯莱英医药集团（天津）股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合 法权益，根据《深圳证券交易所股票上市规则》及《香港联合交易所有限公司证 券上市规则》（经不时修订或补充）等有关法律、法规、规范性文件和《凯莱英 医药集团（天津）股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，结合公司实际情况制定本制度。 第二条 本制度所称舆情信息包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对股票及其衍生品交易价格产生较大影 响的事件信息。 第三条 舆情信息分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经 ...

第一创业证券承销保荐有限责任公司 关于凯莱英医药集团（天津）股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 公司已将上述募集资金存放于为本次非公开发行开立的募集资金专户，并与 保荐机构、存放募集资金的商业银行签署了《募集资金专户存储三方监管协议》。 二、募集资金使用情况 （一）募集资金使用情况 截至 2024 年 9 月 19 日，公司累计使用募集资金 144,921.21 万元，公司利用 闲置募集资金进行现金管理累计收到购买理财产品收益 5,975.97 万元；募集资金 专用账户累计利息收入 1,067.45 万元，手续费支出 2.95 万元。截至 2024 年 9 月 19 日，存放于募集资金专用账户余额为 57,615.33 万元，未到期现金管理余额为 32,000.00 万元。 （二）募集资金暂时闲置原因 募投项目投资建设具有阶段性，募投项目建设中设有多个付款节点，资金在 募投项目完工前会出现暂时闲置情况。 三、前次使用闲置募集资金进行现金管理的情况 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机构"） 作为凯莱英医药集团（天津）股份有限公司（以下简称"凯莱英"或"公司"） ...

证券代码：002821 证券简称：凯莱英 公告编号：2024-087 凯莱英医药集团（天津）股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团(天津)股份有限公司(以下简称"公司")于 2024 年 9 月 30 日召开第四届董事会第五十七次会议，审议通过了《关于使用暂时闲置募集资金 进行现金管理的议案》，拟在确保募投项目正常实施和资金安全的前提下，继续 使用暂时闲置 A 股募集资金不超过 80,000 万元人民币购买保本型理财产品，使 用期限为自董事会审议通过之日起 12 个月内。根据《公司法》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》和《公司章程》等有关规定，本次事项无需提交股东大会审议， 现将有关情况公告如下： 募投项目投资建设具有阶段性，募投项目建设中设有多个付款节点，资金在 募投项目完工前会出现暂时闲置情况。 三、前次使用闲置募集资金进行现金管理的情况 公司于 2023 年 10 月 20 日召开第四届董事会第四十一次会议 ...

证券代码：002821 证券简称：凯莱英 公告编号：2024-088 凯莱英医药集团（天津）股份有限公司 凯莱英医药集团（天津）股份有限公司董事会 二〇二四年九月三十日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 境内同步披露公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司根据《香港联合交易所有限公司证券 上市规则》有关规定，于 2024 年 9 月 30 日在香港联合交易所有限公司披露易 网站（www.hkexnews.hk）刊登了《有关股权出售事项的关连交易》公告。 根据《深圳证券交易所股票上市规则》关于境内外同步披露的要求，特将有 关公告同步披露如下，供参阅。 特此公告。 ...

Financial Performance - Total revenue for the first half of 2024 was RMB 2,655.05 million, a decrease of 42.23% compared to RMB 4,595.71 million in the same period of 2023[12]. - Gross profit for the first half of 2024 was RMB 1,094.70 million, down 54.89% from RMB 2,426.69 million year-on-year[12]. - Net profit attributable to shareholders for the first half of 2024 was RMB 499.13 million, a decline of 70.40% compared to RMB 1,686.37 million in the previous year[12]. - The company reported a gross margin of 41.23% for the first half of 2024, which is a decrease of 11.57 percentage points from 52.80% in the same period last year[12]. - The adjusted net profit attributable to shareholders was RMB 432.72 million, reflecting a 73.56% decrease from RMB 1,636.43 million year-on-year[12]. - The company's revenue for the reporting period was RMB 1,282.25 million, a decrease of 58.59% year-on-year, but a 10.29% increase when excluding the impact of large orders[17]. - Revenue from small and medium-sized companies in the first half of 2024 was RMB 1,372.80 million, down 8.44% year-on-year, with over 1,100 active global customers served[17]. - Overseas business revenue for the company was RMB 1,965.94 million, a decrease of 48.72% year-on-year, but a 3.45% increase when excluding large orders[17]. - Revenue from U.S. customers was RMB 1,741.52 million, showing a significant year-on-year growth of 24.78% when excluding large orders[18]. - The company confirmed revenue from 310 clinical stage projects, generating RMB 787.69 million, a decrease of 7.82% year-on-year[40]. - The company reported total comprehensive income of RMB 498,891 thousand for the six months ended June 30, 2024, compared to RMB 1,693,831 thousand in 2023, reflecting a decrease of 70.6%[166]. Revenue Breakdown - Revenue from small molecule CDMO services was RMB 2,153.42 million, showing a slight increase of 1.09% year-on-year after excluding large orders[14]. - Revenue from emerging business segments was RMB 499.62 million, down 5.30% year-on-year due to a lack of recovery in domestic biopharmaceutical financing[14]. - Revenue from commercialized CDMO solutions was RMB 1,365.73 million, a decline of 57.44% year-on-year, but a growth of 7.06% after excluding large orders[39]. - Revenue from clinical and preclinical CDMO solutions was RMB 787,694,000, a decrease of 7.8% from RMB 854,544,000 in the previous year[186]. - Revenue from commercial stage CDMO solutions was RMB 1,365,725,000, down 57.5% from RMB 3,209,311,000 in the same period last year[186]. - Revenue from emerging businesses was RMB 499,615,000, a slight decrease of 5.3% from RMB 527,592,000 in the previous year[186]. Operational Highlights - The company added 114 new customers during the reporting period, highlighting its operational strength and solid global customer base[14]. - The company aims to further expand its scale despite the termination of large orders, indicating a commitment to growth[14]. - The company is focusing on expanding its customer base and enhancing service depth, particularly in the U.S., Europe, and China markets[24]. - The company anticipates 28 projects to reach the verification batch stage in the second half of 2024, providing strong support for long-term growth[23]. - The company has established partnerships with 16 out of the top 20 global pharmaceutical companies, with 8 of these relationships lasting over 10 years, indicating strong customer loyalty and retention[77]. Research and Development - The company invested RMB 328.69 million in R&D during the first half of 2024, an increase of 1.61% year-on-year, representing 12.38% of total revenue[38]. - Research and development expenses for the period were RMB 328,688 thousand, slightly up from RMB 323,471 thousand in 2023, indicating a focus on innovation despite overall revenue decline[165]. - The company has introduced a tailored talent strategy for each major business segment, hiring 60 senior talents in the first half of 2024, including 33 PhDs[35]. - The company is committed to continuous innovation and has developed internationally recognized patented technologies that are now applied in commercial manufacturing[81]. - The company aims to increase R&D investment to strengthen its research platform and promote smart manufacturing technologies[90]. Financial Position - Cash and bank balances decreased by RMB 1,431.06 million or 20.13% compared to June 30, 2023, primarily due to share repurchases[56]. - The company had no bank borrowings as of June 30, 2024, compared to RMB 12.23 million as of December 31, 2023[56]. - As of June 30, 2024, the company's current assets include inventory of RMB 997,959 thousand, an increase of 5.57% from RMB 945,347 thousand as of December 31, 2023, primarily due to fluctuations from continuous order deliveries[57]. - Trade receivables decreased by 26.23% to RMB 1,483,415 thousand from RMB 2,010,989 thousand, mainly due to the collection of accounts receivable[57]. - The company's total liabilities to total assets ratio increased to 12.76% as of June 30, 2024, from 11.42% as of December 31, 2023[66]. Corporate Governance - The company has complied with the corporate governance code and has not identified any violations by employees during the reporting period[153]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[155]. - The board believes that having the same person serve as both Chairman and CEO will enhance the effective execution of strategic initiatives and improve communication between management and the board[154]. - The company has not faced any investigations or administrative penalties from the China Securities Regulatory Commission during the reporting period[156]. - The company will continue to review and assess the effectiveness of its corporate governance framework[154]. Future Outlook - The company aims to enhance its CDMO services by incorporating advanced drug categories, including peptides, oligonucleotides, and mRNA[76]. - The company is committed to becoming a reliable partner in the global pharmaceutical industry, providing comprehensive CDMO services throughout the drug development lifecycle[76]. - The company plans to enhance its talent acquisition and retention strategies to ensure consistent high-quality service delivery, including tailored training programs and competitive compensation[86]. - The company is currently assessing the impact of the second pillar income tax legislation on its future financial performance, indicating a proactive approach to regulatory changes[190]. - The company plans to utilize the raised funds for various projects, with specific timelines for completion ranging from 2025 to 2026[136][137][138][139].

证券代码：002821 证券简称：凯莱英 公告编号：2024-083 凯莱英医药集团（天津）股份有限公司 关于部分董事、高级管理人员和核心技术及业务人员 增持公司 A 股股份计划的公告 本公司及全体董事会成员、以及部分增持股份的高级管理人员和 核心技术及业务人员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、拟增持股份的规模：不低于人民币 2,000 万元 2、实施期限：自本公告披露之日起 6 个月内（除法律、法规及深圳证券交 易所业务规则等有关规定不允许增持的期间之外） 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于 2024 年 9 月 11 日收到董事张达、洪亮、张婷，高级管理人员姜英伟、陈朝勇、周炎、徐向科 和部分核心技术及业务人员（以下简称"增持主体"）的书面通知，上述增持主 体基于对公司未来持续稳定发展前景的信心以及对公司价值的认可；同时，为促 进公司持续、稳定、健康地发展，维护公司投资者利益，计划以集中竞价交易的 方式增持公司 A 股股份。本次增持不设置固定价格、价格区间，增持主体将根据 公司股票价格波动情况及资本市场整体趋势择机实施增持计划。具 ...

2024 年 09 月 02 日 评级 买入 | --- | --- | |-----------------------|--------------| | | | | 当前价格（元） | 63.67 | | 52 周价格区间（元） | 60.13-164.00 | | 总市值（百万） | 22701.38 | | 流通市值（百万） | 20925.34 | | 总股本（万股） | 36771.90 | | 流通股（万股） | 35620.70 | 涨跌幅比较 凯莱英 医疗服务 -54% -34% -14% 6% 26% 46% % 1M 3M 12M 2023-08 2023-11 2024-02 2024-05 吴号 分析师 执业证书编号: S0530522050003 wuhao58@hnchasing.com 相关报告 凯莱英 -5.39 -15.25 -51.10 医疗服务 -1.60 -12.71 -45.43 1 凯莱英（002821.SZ）2023 年年报点评：常规 业务增长较快，商业化订单储备充足 2024-04-01 2 凯莱英（002821.SZ）2023 年半年报点评：小 分子 CD ...

凯莱英（002821.SZ）/医药生物 证券研究报告/公司点评 2024 年 09 月 03 日 | --- | |-------------------------------------------| | | | [Table_Title] 评级：买入 [Table_Industry] | 分析师：祝嘉琦 执业证书编号：S0740519040001 电话：021-20315150 Email：zhujq@zts.com.cn 分析师：崔少煜 执业证书编号：S0740522060001 Email：cuisy@zts.com.cn [Table_Profit] 基本状况 总股本(百万股) 367.72 流通股本 4,238.1 (百万股) 328.65 市价(元) 62.22 市值(百万元) 22,879.54 流通市值(百万元) 20,448.60 [Table_QuotePic] 股价与行业-市场走势对比 -50.0% 0.0% 50.0% 100.0% 150.0% 200.0% 凯莱英 沪深300 公司持有该股票比例 相关报告 1《凯莱英（002821）-公司点评：剔 除大订单影响主业快速增长，静待 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [9] Core Views - The company has shown steady business development with continuous growth in new orders, despite a significant decline in net profit due to the impact of large orders [5][6] - The small molecule CDMO business remains robust, with emerging services continuing to progress, indicating a strong order backlog and future growth potential [6][8] - The company has successfully expanded its overseas operations and new business capacities, enhancing its market presence [8] Summary by Sections Company Overview - Latest closing price is 63.67 yuan, with a total market capitalization of 234 billion yuan and a circulating market capitalization of 209 billion yuan [1] - The company has a low debt ratio of 11.4% and a price-to-earnings ratio of 10.17 [1] Financial Performance - For the first half of 2024, the company reported revenue of 2.697 billion yuan, a year-on-year increase of 41.63%, while net profit attributable to shareholders decreased by 70.40% to 499 million yuan [5] - The small molecule CDMO business generated revenue of 2.195 billion yuan, showing a decline of 46.28%, but a slight increase of 2.49% when excluding large orders [6] Profitability and Cost Management - The gross margin for the first half of 2024 was 42.15%, down 10.91 percentage points year-on-year, with effective control over expense ratios [7] - The company maintained a sales expense ratio of 3.80% and a management expense ratio of 13.42% for the first half of 2024 [7] Order Growth and Capacity Expansion - The company added 114 new clients in the first half of 2024, with new orders increasing by over 20% year-on-year, particularly from the European and American markets [8] - The company has established a new R&D and pilot base in the UK, enhancing its operational capabilities in Europe [8] Earnings Forecast - The company is projected to achieve net profits of 1.214 billion yuan, 1.566 billion yuan, and 2.067 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 3.30, 4.26, and 5.62 yuan [9]

二〇二四年八月三十一日 | --- | --- | --- | |----------------------|---------------------------------------------------------------------------------------------|------------------------------------------| | | | | | 证券代码： | 002821 证券简称：凯莱英 公告编号： | 2024-081 | | | 凯莱英医药集团（天津）股份有限公司 | | | 关于参加 | 2024 年度天津辖区上市公司半年报业绩说明会 | | | | 暨投资者网上集体接待日的公告 | | | | 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 | | | | 为进一步加强与投资者的互动交流，凯莱英医药集团（天津）股份有限公司 | | | （以下简称 " | 公司 " ）将参加由天津证监局、天津上市公司协会与深圳市全景网络 | | | 有限公司联合举办的 | "2024 年度天津辖区上市公司半年报 ...